A stability indicating RP-HPLC method is developed and evaluated to quantify sofosbuvir and velpatasvir in raw and tablets forms. The method involves separation and analysis of sofosbuvir, velpatasvir and their stress degradants using Spursil C18 (250 × 4.5 mm and i.d., 5 µm particle size) analytical column with a mixture of potassium dihydrogen phosphate (0.1 M) and methanol (pH 4.5, 60:40 v/v) as the mobile phase. The analysis was done using a photodiode array detector at 240 nm. Calibration curves showed linearity in concentration range 10-30 (velpatasvir) and 40-120 µg/mL (sofosbuvir). Good linearity (R 2 ≥ 0.9998), good precision (RSD ≤ 0.138%, n = 5) and good accuracy (% recovery ̴ 100%) for velpatasvir and sofosbuvir were achieved. Stress degradation studies were performed on powdered tablet sample in athe cidic, basic, oxidative, thermal and photolytic atmosphere. The method showed no interference from the degradation products formed by applied stress conditions. Application of the proposed method to the commercially available tablets was carried out successfully. The performance of the proposed method was compared with those from previously published HPLC methods and they were satisfactory.
INTRODUCTION
Hepatitis C is a chronic infection by hepatitis C virus with nearly 130-150 million of the population infected globally 1, 2 . Hepatitis C virus is a single-stranded ribonucleic acid virus belonging to the family Flaviviridae. The most important objective of hepatitis C virus therapy is to obtain a sustained virological response, resulting in complete eradication of Hepatitis C viral RNA levels, within 24 weeks following completion of treatment 3 . A tablet dosage combination of velpatasvir and sofosbuvir was approved in June 2016 by the United States Food and Drug Administration in treating hepatitis C virus-infected patients 4, 5 . Sofosbuvir (a phosphoramidate prodrug) undergoes extensive intracellular metabolism to form deoxy-α-fluoro-β-C-methyluridine triphosphate (active antiviral agent). This active antiviral agent is a defective substrate for non-structural protein 5B which is required for transcription of viral RNA 6 . Velpatasvir inhibits hepatitis C virus non-structural protein 5A and possesses potent antiviral activity against all genotypes. Non-structural protein 5A is required for viral replication 7 . The chemical structures of the sofosbuvir and velpatasvir are given in In Sarath & Rao method, separation and analysis were done using Discovery® C18 column with orthophosphoric acid plus acetonitrile (60:40 v/v) at a flow rate of 1.0 mL/min 8 as mobile phase. UV detection was performed at 240 nm. Uppalapati & Parimi achieved separation using mobile phase having 0.1% trifluoro acetic acid: methanol (42:58 vol/vol) on an XTerra RP18 column 9 . 1.0 mL/min is the flow rate and 269 nm is used for detecting analytes. Present work describes validated rapid, precise, accurate stability indicating RP-HPLC method in the quantitation of sofosbuvir & velpatasvir combination in raw and tablets. 
EXPERIMENTAL
Instrumentation HPLC system (Waters) with binary HPLC pump (model number 2695), PDA detector (model number 2998) and degasser with 10 µL injection loop were used. The chromatographic data was processed by Waters Empower2 software. Electronic balance ELB 300 and Digisun pH meter were used.
Materials
Lara Drugs Private Limited (Hyderabad, Telangana, India) was kind enough in providing sofosbuvir and velpatasvir reference substances. Sovihep V tablets having 400 mg of sofosbuvir & 100 mg of velpatasvir (Zydus Heptiza, Ahmedabad, India) were obtained from commercial sources. Methanol of HPLC grade was acquired from Merck Pvt Ltd. (Mumbai, Maharashtra, India). Potassium dihydrogen phosphate, orthophosphoric acid, hydrochloric acid, hydrogen peroxide and sodium hydroxide of analytical reagent grade were acquired from Sd Fine Chemicals Ltd. (Mumbai, Maharashtra, India). Water purified via Milli-Q system was used in the study.
Chromatographic Conditions
The chromatographic separation and analysis of selected drug combination were worked out on a Spursil C18 (250 × 4.5 mm, i.d., 5 µm particle size). The mobile phase used is a mixture of 10 -1 M potassium dihydrogen phosphate & and methanol (pH 4.5, 60:40 v/v). 1 mL/min is the flow rate. Mobile phase filtration using 0.45 µm membrane filter was done and 10 min sonication was performed. The column temperature is 25±2 o C while analyzing. The analyte elution was monitored using a photodiode array detector set at 240 nm. 10 µL is the injection volume.
Solutions of Stock Standard and Tablet Sample
The stock solution was prepared by weighing 400 mg sofosbuvir & 100 mg velpatasvir, and dissolved in 30 mL of mobile phase in a volumetric flask having 100 ml capacity. A concentration of 4000 µg/mL and 1000 µg/mL of sofosbuvir and velpatasvir was achieved by the mobile phase to the final volume of the volumetric flask. The prepared solution was further diluted using mobile phase to attain working standards having concentration 10, 15, 20, 25 & 30 µg per mL for velpatasvir and 40, 60, 80, 100 & 120 µg per mL for sofosbuvir. Ten tablets of Sovihep V (400 mg sofosbuvir and 100 mg velpatasvir /tablet) were powdered. Tablet powder equal to 400 mg sofosbuvir & 100 mg velpatasvir is accurately weighed into a volumetric flask having 100 ml capacity and mixed with 30 milli liters mobile phase. Sonication of solution performed for 20 minutes and filled by mobile phase for obtaining a final concentration of 1000 µg/mL velpatasvir and 4000 µg/mL sofosbuvir. Filtration of the solution was through 0.45 µm membrane. For analyzing the analytes, the above-prepared tablet sample solution was diluted further to reach a concentration of 80 µg/mL and 20 µg/mL sofosbuvir and velpatasvir, respectively with the mobile phase.
Degradation Study
In this study, acidic, basic, oxidative, thermal, and photolytic degradation of tablet solution (20 µg/mL velpatasvir & 80 µg/mL sofosbuvir) were studied 10 . Acid and base degradation studies were performed using tablet powder equivalent to 400 mg sofosbuvir and 100 mg velpatasvir in HCl (0.1 N, 10 mL) and NaOH (0.1 N, 10 mL), respectively and sonicated at room temperature for 30 min. For oxidative degradation, the same concentration of tablet sample was used in 30% hydrogen peroxide (10 mL) followed by sonication at room temperature for 30 min. Thermal and photolytic degradation studies were performed on tablet powder (equivalent to 400 mg sofosbuvir and 100 mg velpatasvir). The tablet powder was exposed to 105 o C for 30 min in oven (thermal degradation) or to sun light for 1 day (photolytic degradation). After degrading, tablet solution was prepared as explained in "stock standard and tablet sample solutions" section. After the application of stress on the tablet sample, the stressed samples dilution was done by mobile phase to a concentration of 20 µg per mL velpatasvir & 80 µg per mL sofosbuvir for analysis. The degraded samples are filtered and then injected into the HPLC system. Calculation of peak area for velpatasvir & sofosbuvir were noted from the respective chromatogram. Working standard solution at the same concentration level was used to calculate the percentage of the drug remained in each degradation condition. The peak purity of velpatasvir and sofosbuvir was also determined in all the degradation conditions.
RESULTS AND DISCUSSION

Method Optimization
Parameters of chromatography parameters -a time of retention, peak tailing, theoretical plates count, and resolution were determined to optimize the method. For that, trials are carried out -different mobile phase ratios and different stationary phase types, with temperature difference, values of pH and flow rate. On this basis method is employed to separate velpatasvir and sofosbuvir from themselves and also from stress degradants, Spursil C18 (250 × 4.6 mm, 5 µm) column having temperature 25±2 o C was selected which gave good symmetric and sharp peaks. Based on less analysis time, peak response, peak symmetry and column efficiency, a mixture of methanol and 10 -1 M potassium dihydrogen orthophosphate and methanol (40:60 v/v) was selected as mobile phase with adjustment pH to 4.5 units and 1.0 millilitre/minute flow rate, using photodiode array detector, a wavelength of 240 nm was selected as detection wavelength. The chromatographic parameters optimized exhibit a good peak shape, resolution and a good number of theoretical plates. The typical chromatogram of velpatasvir and sofosbuvir by the developed method is presented in Fig. -3 . 
Method Validation
Validation was performed by referring ICH guidelines 11 . HPLC Suitability, linearity, selectivity, accuracy, sensitivity, precision, specificity and robustness were determined.
System Suitability Study
System suitability established by five consecutive injections with the same working standard solutions. Parameters considered were: USP plate count, USP tailing, USP resolution, peak areas' and retention times' relative standard deviation of velpatasvir and sofosbuvir. The values for the system suitability parameters of the method, as presented in Table- 1, are within acceptance limits. 
Selectivity
The selectivity of the optimized HPLC method was examined with standard working solution of velpatasvir (20 µg per mL) & sofosbuvir (80 µg per mL) relative to the placebo blank, blank mobile phase and tablet sample solution (velpatasvir -21 µg/mL and sofosbuvir -80 µg/mL) (Fig. -4) . No interference was observed by coelution of the excipients in placebo blank, components of the mobile phase at the same retention time of velpatasvir and sofosbuvir at 240 nm, demonstrating the selectivity of this method. The time of velpatasvir & sofosbuvir retention in working solution and tablet solution are alike. 
Precision and Accuracy
For precision studies, the same standard solutions of velpatasvir and sofosbuvir were injected 6 times into the HPLC system on the same day. The percentage RSD values calculated for peak areas of velpatasvir and sofosbuvir were less than 0.2 % ( Table-3 ) indicating the precise assay with the developed HPLC method. For accuracy, the percentage recovery was calculated for both active ingredients. The results ( Table-3 ) are acceptable with good percent recovery. 
Recovery Test
Further evaluation of the accuracy of the method was carried through recovery test. Recovery test was determined by means of the standard addition method. The recovery experiments were performed by adding velpatasvir and sofosbuvir standards at three concentration levels to the placebo for three times. The recovery test results are summarized in Table 4 . Hence, the obtained results indicated that the developed HPLC method was accurate enough for simultaneous quantitative evaluation of aspirin and pravastatin. There was no interference noticed from the common excipients of the tablet. 
Robustness
Under the slightly varied chromatographic conditions (mobile phase's flow rate -±0.1 mL/min & temperature in the column -±2 o C), velpatasvir and sofosbuvir peaks were well separated and there was no significant change in the system suitability parameters (Table-5 ), which illustrated the robustness of the method. 
Degradation Studies
Solutions of velpatasvir and sofosbuvir tablet are stressed under acidic, oxidative, alkali, thermal & photolytic conditions. Method's ability of stability indication and specificity are tested pertaining to the above-said conditions. Results of degradation studies are provided in Table-6 . Degraded sample's chromatograms shown in Fig. -5 . The degradation percentage was estimated from the peak area obtained in degradation conditions and it was compared with the assay of the nondegraded condition. Both the drugs were degraded in all the stress conditions applied. In the entire degradation conditions, one degradant peak is observed. From the results, it was observed that the velpatasvir is degraded more in thermal & less in oxidative degradations. Sofosbuvir degradation is more in acid condition but less in thermal degradation. The peak purity profile of velpatasvir and sofosbuvir was determined. The less value of purity angle than purity threshold value showed that velpatasvir & sofosbuvir peaks are homogeneous in every condition of degradation. Method's nature of stability indication & specificity is demonstrated because degradation products of applied stress have no any effect on the detection and quantitation of velpatasvir and sofosbuvir.
Comparison of the Proposed Method with Reported Methods
Two HPLC methods are done on simultaneous evaluation of velpatasvir & sofosbuvir in tablet forms 8, 9 . Performance of reported and proposed HPLC methods is summarized in Table-7. From the values in the  Table- 
CONCLUSION
In this study, an RP-HPLC method which is stability indicating was optimized and validated for determining velpatasvir & sofosbuvir in raw and tablets. The method was rapid, cost-effective, accurate & precise with good selectivity and specificity. Results of this method validation showed that the method was satisfactory and so this method can be applicable in regular quality control laboratories. 
